Teva Pharmaceutical Industries (TEVA, Financial) saw a significant stock price increase of 5.02%, with shares trading at $18.11. The trading volume reached 4.41 million shares, reflecting a turnover rate of 0.39% and a price fluctuation of 4.61%.
Recent financial reports reveal that Teva generated $4.162 billion in revenue, despite a net loss of $845 million. Earnings per share stood at -$0.75, with a gross profit of $2.022 billion. The price-to-earnings ratio is currently at -46.37. Among 12 rating institutions, 67% recommended the stock as a buy, while 33% suggested holding. No institutions advised selling.
In the broader pharmaceutical sector, which overall declined by 0.61%, other notable stock movements included significant activity from companies like Scilex Holding and Su Xuantang. Su Xuantang saw a substantial turnover rate of 19.07%, and significant price swings were observed in stocks such as Incannex Healthcare.
Teva, headquartered in Israel, is a leading global producer of generic medicines, deriving half its sales from North America. The company also has a strong presence in Europe, Japan, Russia, and Israel. Beyond generics, Teva offers a range of innovative and biosimilar drugs across three main therapeutic areas, including central nervous system medications such as Copaxone, Ajovy, and Austedo, respiratory treatments like Qvar and ProAir, and oncology products including Truxima, Herzuma, and Bendeka/Treanda. Additionally, Teva markets active pharmaceutical ingredients, provides contract manufacturing services, and owns Anda, a U.S.-based distributor of generic and specialty medicines.
